140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trialV. Guarneri, Aleix Prat, M. Marin et al.|Annals of Oncology|2022Cited by 1
97P Genomic bases of endocrine sensitivity in triple-positive early breast cancer: A translational analysis of the PerELISA trialGaia Griguolo, V. Guarneri, Maria Vittoria Dieci et al.|Annals of Oncology|2022Cited by 0